Beth Israel Deaconess Medical Center (BIDMC) is a major teaching hospital of Harvard Medical School. The BIDMC oncology faculty consists of an exceptional group of committed basic and clinical investigators. BIDMC is home to nationally recognized centers of expertise focused on breast cancer, melanoma, renal cancer, prostate cancer, ovarian cancer, pancreatic cancer, hepatic cancer and hematologic malignancies. Areas of renowned scientific expertise include: vaccine and cytokine therapy, angiogenesis Inhibition and targeted therapy. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes ail Harvard Medical School affiliated Institutions. This arrangement enables the leveraging of scientific and clinical cancer research expertise across all Harvard institutions, enabling the creation of translational and clinical research entities. For example, since its founding, the DF/HCC has successfully competed for 8 SPORE grants (Breast, Skin, Kidney, Prostate, Ovarian, Myeloma and Lung), with BIDMC investigators being active participants in virtually all of these. Cancer clinical trials support is provided by a dedicated Cancer Clinical Trials Office (CCTO) which provides regulatory, administrative, educational and quality assurance support for 11 disease-based multi-disciplinary clinical research programs. BIDMC has been a main ECOG institution since 1997 and has been a main institution since 1998. Over the initial 11 years of funding, BIDMC investigators have consistently recruited 40-80 patients per year to therapeutic and prevention trials. To date, in 2009, BIDMC has accrued 30 patients to therapeutic trials. The BIDMC ECOG grant supports 3 affiliate institutions. BIDMC investigator scientific and administrative participation in ECOG activities, data quality, data delinquency rates and affiliate accrual have all steadily increased over the past funding period. With the transition of research protocols to DF/HCC IRB and the creation of CCTO infrastructure now complete, the BIDMC stands poised to enhance our laboratory and clinical research contributions and increase our participation in ECOG related activities.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
DiPaola, Robert S; Chen, Yu-Hui; Bubley, Glenn J et al. (2015) A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 68:365-71
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Hodi, F Stephen; Lee, Sandra; McDermott, David F et al. (2014) Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312:1744-53
Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B et al. (2014) Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution. J Interferon Cytokine Res 34:376-84
Liu, Glenn; Chen, Yu-Hui; Kolesar, Jill et al. (2013) Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol 31:211-8
Karp, Daniel D; Lee, Sandra J; Keller, Steven M et al. (2013) Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. J Clin Oncol 31:4179-87
Liu, Glenn; Chen, Yu-Hui; Dipaola, Robert et al. (2012) Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 10:99-105

Showing the most recent 10 out of 17 publications